High Prevalence of Bone Marrow Disorders is expected to Propel Growth of the Thrombocytopenia Treatment Market

Thrombocytopenia or thrombosed blood refers to a condition where there is an excessive accumulation of blood clots in the vessels. They occur when the blood flow to a certain part of the body is blocked and therefore they lead to an accumulation of blood in the vessels, which causes them to clot. The accumulated blood clots are usually harmless but can cause severe pain and even difficulty in breathing. If left untreated, the condition can also result in serious heart diseases, stroke, paralysis and death.
It can be caused by an underlying condition like high blood pressure, atherosclerosis, and other heart diseases. In addition, people with cancer, liver disease, heart disease and diabetes are also more likely to suffer from thrombocytopenia. For some people, however, this condition can also be triggered by stress and anxiety. It can also result from poor health habits such as smoking, alcohol intake, and obesity.

High prevalence of bone marrow disorders is expected to propel growth of the thrombocytopenia treatment market. For instance, according to National Cancer Institute, the number of estimated new cases of leukemia in 2019 in the U.S. was 61, 780. 

Major players operating in thrombocytopenia treatment market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2020, Rigel Pharmaceuticals, Inc. and Medison Pharma announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to other treatments.

Competitive Analysis
Major players operating in thrombocytopenia treatment market include, 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.

Major players operating in thrombocytopenia treatment market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2020, The U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to the oral investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, which has the potential to be the first BTK inhibitor for the treatment of immune thrombocytopenia.


 

Comments

Popular posts from this blog

Let’s know what is Automotive Internet of Things? Why it is gaining so much importance in the automotive industry?

Increasing Prevalence of Sleep Disorders to Augment Growth of the Sleep Aids Market

Increasing Demand for Disinfecting Wipes Is Expected To Boost the Household Wipes Market Growth